Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. (EPRX) generates a steady flow of news as a clinical-stage biotechnology company advancing drug candidates built on its Diffusphere™ drug delivery platform. Company updates focus on clinical data readouts, trial progress, financing events, and operational developments tied to its lead programs in eosinophilic esophagitis (EoE) and osteoarthritis.
A central theme in Eupraxia’s news is the RESOLVE trial for EP-104GI in EoE. Press releases detail Phase 1b/2a dose-escalation results, including tissue health outcomes measured by the EoE Histological Scoring System, symptom improvements via the Straumann Dysphagia Index, durability of response out to 52 weeks after a single administration, and safety and tolerability observations such as the absence of reported Serious Adverse Events and candidiasis in disclosed cohorts. Additional news covers the transition into and expansion of the randomized, placebo-controlled Phase 2b portion of RESOLVE and plans to increase patient numbers and dose levels.
Investors following EPRX news will also see pipeline and platform updates, including references to EP-104IAR for knee osteoarthritis and Eupraxia’s broader pipeline of long-acting formulations for inflammatory joint indications, oncology, and other potential disease areas. Financing announcements, such as public offerings of common shares under Canadian and U.S. prospectuses, provide context on how the company funds its clinical and preclinical programs, regulatory submissions, and manufacturing scale-up.
This news feed brings together clinical trial milestones, financial results, capital markets transactions, and conference participation disclosed by Eupraxia. Readers can use it to track how EP-104GI and EP-104IAR progress through development, how the Diffusphere™ platform is being applied across indications, and how management describes risk factors, cash runway, and strategic priorities over time.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) announces that Dr. Amanda Malone, Chief Operating and Scientific Officer, will present at the Controlled Release Society 2024 Annual Meeting and Expo in Bologna, Italy, from July 8-12, 2024.
The presentation, titled 'EP-104, a novel microparticle formulation achieving extended-release of fluticasone propionate,' will occur on July 10, 2024, from 9:00 AM to 11:00 AM CEST (3:00 AM to 5:00 AM ET) during the 'Long-Acting Drug Delivery Formulations - Session #2'. The presentation can be accessed online at Eupraxia's website.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX), a clinical-stage biotech firm utilizing its proprietary DiffuSphere™ technology, announced that its CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar titled, "Exploring The Rapid Rise of Osteoarthritis." The event is set for July 9, 2024, at 8:30 am PT / 11:30 am ET. Osteoarthritis is a leading cause of disability among older adults, with knee OA affecting over 30 million people in the U.S. alone. Registration for this public event is open, and questions for Dr. Helliwell can be submitted via Tribe Public’s email or ZOOM chat during the event. John F. Heerdink, Jr. from Tribe Public will moderate the session.
Eupraxia Pharmaceuticals, a clinical-stage biotech firm, announced the results of its Annual General and Special Meeting of Shareholders held on June 6, 2024. All six board nominees were elected, with votes overwhelmingly in favor. KPMG LLP was appointed as the auditor, and several business items, including stock option plans and potential share consolidations, were approved. Eupraxia focuses on extended-release drug delivery through its DiffuSphere™ technology. The company recently completed a successful Phase 2b trial for osteoarthritis and is expanding into gastrointestinal treatments with ongoing trials.
Eupraxia Pharmaceuticals announced that it will present data from its Phase 2 SPRINGBOARD study on EP-104IAR, a treatment for knee osteoarthritis, at the EULAR European Congress of Rheumatology 2024 in Vienna, Austria. The study assesses the efficacy of a long-acting fluticasone propionate intra-articular injection compared to a vehicle placebo. The presentation, under programme number OP0274, will occur on June 14, 2024, from 10:50 AM to 11:00 AM CEST. Further details will be available on the company's website.
Eupraxia Pharmaceuticals announced the expansion of its RESOLVE Phase 1b/2a trial for EP-104GI to treat eosinophilic esophagitis (EoE). Encouraging early-phase results with eight of nine patients responding positively and exhibiting good safety profiles spurred this decision. The expansion will allow for higher doses and longer follow-up periods, now up to 52 weeks. The study will include more participants, increasing from 12-15 to 27-33. Additional clinical sites will be established to support the new recruitment targets. The trial aims to gather data to support a potential registration trial in 2025.
Eupraxia Pharmaceuticals will host a virtual key opinion leader (KOL) event on May 29, 2024, at 10:00 AM ET to discuss their EP-104GI clinical development program for Eosinophilic Esophagitis (EoE). The event will feature Dr. Evan S. Dellon, a leading expert from the University of North Carolina, alongside company management. The focus will be on data from the Phase 1b/2a RESOLVE trial and the potential of Eupraxia's DiffuSphere™ technology to enhance treatment outcomes for EoE patients. A live Q&A session will follow.
Eupraxia Pharmaceuticals announced positive data from its Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE). Results from the first and second cohorts showed potential efficacy up to 24 weeks, with improved symptom outcomes and reduced eosinophil counts. The third cohort, receiving a higher dose, also reported symptom improvements at 12 weeks. The treatment demonstrated a strong safety profile with only mild to moderate adverse events. Eupraxia plans to continue data disclosure as the trial progresses.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) announced that it will present initial results from its ongoing Phase 1b study of EP-104GI at the Digestive Disease Week (DDW) Annual Meeting 2024, held in Washington, D.C., from May 18-21, 2024.
The study focuses on treating eosinophilic esophagitis using EP-104GI, a long-acting injectable suspension of fluticasone propionate. Chief Scientific Officer Amanda Malone, PhD, will deliver a poster presentation on May 18, 2024.
The presentation details are: Abstract: 4031521, Session Type: Poster Session, Session Title: Eosinophilic Esophagitis and Gastroenteritis: Clinical, and Session Date & Time: May 18, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4).
Further details will be available on Eupraxia's website.
Eupraxia Pharmaceuticals reported its first quarter 2024 financial results and provided a corporate update, highlighting achievements such as listing on Nasdaq, progress in clinical studies, and financial performance. Notable milestones include the presentation of positive clinical data, initiation of Phase 3 development programs, and securing funding through public offerings. The company's focus on optimizing drug delivery technology and advancing treatments for conditions like osteoarthritis shows promise for future growth and development.
Eupraxia Pharmaceuticals has announced the formation of a Clinical Advisory Board for its gastrointestinal program, specifically focusing on the EoE treatment. The board consists of renowned experts in the field who will guide the development of EP-104GI for eosinophilic esophagitis. The company aims to address the unmet medical needs of the EoE patient population with their proprietary DiffuSphere™ technology.